65,437 trials
Uterine Cervical Neoplasms
Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator — 47.6; 47.5 Months — p=0.0004
Non-cystic Fibrosis Bronchiectasis · Pseudomonas Aeruginosa · Lung Infection
Primary: P. Aeruginosa Recovery in Sputum Following Multiple Doses of AP-PA02 Administered by Inhalation — -0.5; -0.1; -0.4; 1.0 colony forming units log10
Alcohol Abuse
Primary: Changes in Alcohol-influenced Behavior — 1.56; 1.49 units on a scale
Type 2 Diabetes Mellitus in Obese
Primary: Change From Baseline in Participants' HbA1c — -2.3; -2.4 mmol/mol — p=0.8
Non-Small Cell Lung Cancer
Primary: Overall Response Rate — 0.0; 0.0 percentage of participants
Alzheimer Disease
Primary: Change in Plasma Amyloid Beta (Aβ) Levels — -0.38; 0.02; 0.24; -0.08 Z-score — p=0.003
Myocardial Infarction · Iron-deficiency
Primary: Decrease in the Wall Motion Score Index — 53; 58; 46 Participants
Speech Sound Disorder
Primary: Change in F3-F2 Distance (Hz) Across Sessions, Measured From /r/ Sounds Produced in Syllables or Words During Practice. — 38.2; 66.7; 85.2 Hertz / session — p=< .0001
Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage III Breast Cancer AJCC v8
Primary: Physical Function at End-of-intervention — 9.2; 9.1 score on a scale
Multiple Sclerosis
Primary: Annualized Relapse Rate (ARR) — 0.04; 0.03 relapses per year
Influenza
Primary: Percentage of Subjects With Seroconversion Antibody Titer — 47.1; 36.8; 63.8; 37.3 percentage of participants
COVID-19
Primary: Number of Participants With Completed COVID-19 Tests — 73 Participants — p=.05
Asthma
Primary: Change From Baseline in the Proportion of Patients With an ICS-based Maintenance and/or Reliever Treatment — 571; 723 Participants — p=<.0001
Depressive Disorder, Major · Anhedonia
Primary: Change From Baseline to Day 43 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -9.4; -10.0 Units on a scale — p==0.670
Anterior Cruciate Ligament Injury
Primary: Immediately Post NMES+ECC Intervention Isokinetic Quadriceps Strength Index — 60.9; 58.4 Percentage — p=.025